VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ESMO Breast 2020 | Immunotherapy for TNBC: IMpassion130 & KEYNOTE-355

Sara Tolaney • 19 May 2020
ESMO Breast 2020
Breast Cancer Antibodies Atezolizumab Checkpoint Inhibitors Gemcitabine Nab-paclitaxel
IMpassion130 Immuno-Oncology

Sara Tolaney, MD, MPH, Dana Farber Cancer Institute, Boston, MA, outlines the role of immunotherapy in triple-negative breast cancer (TNBC), discussing IMpassion130 (NCT02425891) and KEYNOTE-355 (NCT02819518) trials. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Sara Tolaney

1:59
monarchE: patient-reported outcomes
Sara Tolaney • 19 Mar 2021
2:03
mTNBC: tumor mutational burden & PTEN Alterations as molecular correlates
Sara Tolaney • 14 May 2020
1:58
ASCENT-04: sacituzumab govitecan and pembrolizumab in PD-L1-positive TNBC
Sara Tolaney • 13 Sep 2022
2:35
What does the future hold for SERDs in ER+ breast cancer?
Sara Tolaney • 13 Sep 2022

Related Videos

1:01
Highlights in breast and gynecological cancer at ESTRO 2022
Pedro Lara
1:52
What impact will biosimilars have on clinical life?
Diana Lüftner
1:22
Drug shortages around the world: why communication is key
Fatima Cardoso
2:13
HER-2 conversion: a phenomenon in trastuzumab resistance
Russell Petty
VJOncology VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJOncology is intended for healthcare professionals